Arsenic Exposure Perturbs the Gut Microbiome and Its Metabolic Profile in Mice: An Integrated Metagenomics and Metabolomics Analysis by Lu, Kun et al.
284 volume 122 | number 3 | March 2014 • Environmental Health Perspectives
Research All EHP content is accessible to individuals with disabilities. A fully accessible (Section 508–compliant) HTML version of this article is available at http://dx.doi.org/10.1289/ehp.1307429. 
Introduction
The human body is host to 100 trillion gut 
microbes, approximately 10 times more than 
all human cells (Ley et al. 2006). Ley et al. 
(2006) estimated that the approximately 
500–1,000 species residing in the human 
gut encode 100-fold more unique genes than 
the human genome. The gut microbiota has 
important functions in metabolic processing, 
energy production, immune cell development, 
food digestion, epithelial homeostasis, and so 
forth (Young et al. 2008). Mounting evidence 
indicates that dysregulated gut microflora 
contributes in a significant way to a variety of 
diseases, including diabetes, obesity, cardio-
vascular diseases, allergies, inflammatory bowel 
disease, and others (Ley et al. 2005; Qin et al. 
2012; Wang et al. 2011). For example, obese 
individuals exhibit a remarkable reduction in 
the abundance of Bacteroidetes and a relative 
increase in Firmicutes compared with lean 
individuals (Turnbaugh et al. 2006). Likewise, 
a metagenome- wide association study revealed 
that beneficial butyrate-producing bacteria are 
less abundant and that opportunistic patho-
gens are more abundant in individuals with 
diabetes than in healthy individuals (Qin et al. 
2012). The gut micro biome evolves through 
several transitions during the first years of life 
and thereafter remains relatively constant if no 
significant perturbations occur. However, the 
composition of the gut microbiome is highly 
diverse, and this diversity can be readily affected 
by external factors such as environ ment, diet, 
bacterial/viral infection, and antibiotics. This 
raises the possibility that exposure to toxic 
environ mental chemicals leads to gut micro-
biome alteration (dys biosis) as a mechanism 
by which environmental agents exert their 
detrimental effects on human health.
Arsenic exposure affects large human 
populations worldwide, with contamination of 
drinking water by geological sources of inor-
ganic arsenic being the primary route of expo-
sure. Hundreds of millions of people around 
the world, especially in South and East Asia, 
drink water with arsenic levels that far exceed 
the 10-μg/L guideline established or accepted 
by the World Health Organization and the 
U.S. Environmental Protection Agency (EPA)
(Hughes et al. 2011). In the United States, 
as many as 25 million people are estimated 
to drink water with an arsenic level > 10 μg/L 
because private wells are not regulated by the 
U.S EPA and other agencies (Kozul et al. 
2009). Arsenic exposure has been associated 
with a number of diseases such as skin, 
bladder, lung, and liver cancers and diabetes, 
as well as cardio vascular disorders (Hughes 
et al. 2011; Van de Wiele et al. 2010). More 
recently, arsenic exposure has been linked to 
an increased incidence of diabetes in animal 
models and human population studies (Paul 
et al. 2011). Numerous mechanisms have been 
proposed for arsenic-induced diseases, includ-
ing interactions between arsenic and sulfur, oxi-
dative stress, genotoxicity, altered DNA repair 
and signal transduction, cell proliferation, and 
epigenetics (Hou et al. 2012; Hughes et al. 
2011; Ren et al. 2011; Smeester et al. 2011). 
Accumulating evidence indicates that pertur-
bations of the gut microbiome and its influ-
ence on metabolic and physiological functions 
may play an important role in the development 
of human diseases. Given the essential role of 
the gut microbiome in a variety of aspects of 
human health coupled with the high toxicity of 
arsenic, there is a need to elucidate the effects 
of arsenic exposure on the gut microbiome 
and its functions. In particular, several seminal 
studies have reported interactions between the 
gut micro biome and environmental chemicals 
such as arsenic, mercury, polycyclic aromatic 
hydrocarbons, and polychlorinated biphenyls 
(Choi et al. 2013; Liebert et al. 1997; Pinyayev 
et al. 2011; Van de Wiele et al. 2005, 2010).
The gut microbiome has profound roles 
in modulating host metabolism. For example, 
non digestible carbohydrates are degraded via 
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Background: The human intestine is host to an enormously complex, diverse, and vast microbial 
community—the gut microbiota. The gut microbiome plays a profound role in metabolic processing, 
energy production, immune and cognitive development, epithelial homeostasis, and so forth. 
However, the composition and diversity of the gut microbiome can be readily affected by external 
factors, which raises the possibility that exposure to toxic environmental chemicals leads to gut 
microbiome alteration, or dysbiosis. Arsenic exposure affects large human populations worldwide 
and has been linked to a number of diseases, including cancer, diabetes, and cardiovascular disorders.
oBjectives: We investigated the impact of arsenic exposure on the gut microbiome composition 
and its metabolic profiles.
Methods: We used an integrated approach combining 16S rRNA gene sequencing and mass 
spectrometry– based metabolomics profiling to examine the functional impact of arsenic exposure 
on the gut microbiome.
results: 16S rRNA gene sequencing revealed that arsenic significantly perturbed the gut micro-
biome composition in C57BL/6 mice after exposure to 10 ppm arsenic for 4 weeks in drinking 
water. Moreover, metabolomics profiling revealed a concurrent effect, with a number of gut 
microflora–related metabolites being perturbed in multiple biological matrices.
conclusions: Arsenic exposure not only alters the gut micro biome community at the abundance 
level but also substantially disturbs its metabolic profiles at the function level. These findings may 
provide novel insights regarding perturbations of the gut microbiome and its functions as a potential 
new mechanism by which arsenic exposure leads to or exacerbates human diseases.
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fermentation by the gut bacteria to yield energy 
for microbial growth and microbial end prod-
ucts that act as energy substrates, inflammation 
modulators, and signaling mole cules (Holmes 
et al. 2011). Therefore, the reach of the gut 
microbiome on host metabolism extends well 
beyond local effects in the gut to diverse remote 
organ systems, such as liver, brain, adipose, and 
muscle (Claus et al. 2011; Diaz et al. 2011). 
Accumulating evidence indicates that metabolic 
perturbations associated with changes in the 
gut micro biome composition are important 
risk factors for developing diseases (Jones et al. 
2008; Wang et al. 2011). For example, gut 
microflora–generated trimethylamine N-oxide 
from dietary choline and carnitine has been 
strongly associated with athero sclerosis in ani-
mal models and clinic cohorts (Wang et al. 
2011). Therefore, it is of particular interest to 
probe the gut microbiome–related metabolic 
changes associated with an arsenic-perturbed 
gut microbiota community. In this aspect, mass 
spectrometry– based metabolomics profiling is 
highly attractive because of its high sensitivity, 
ability to detect molecules with diverse struc-
tures, wide dynamic range, quantitative capabil-
ity, and ease of interfacing with other separation 
techniques such as liquid chromatography (Lu 
et al. 2012).
In the present study, we applied an inte-
grated approach combining 16S rRNA gene 
sequencing and liquid chromatography–mass 
spectrometry (LC-MS) metabolomics to 
analyze the effects of arsenic exposure on the 
gut microbiome and its metabolite profiles. 
Metagenomics sequencing revealed that arsenic 
exposure significantly perturbed the gut micro-
biome composition in C57BL/6 mice. Our 
nontargeted metabolomics profiling revealed 
a notable effect of arsenic exposure in these 
mice, with diverse perturbed metabolites being 
corelated with gut microbiome changes.
Materials and Methods
Animals and exposure. Specific-pathogen-
free C57BL/6 female mice (~ 6 weeks of age) 
were purchased from Jackson Laboratories 
(Bar Harbor, ME). Mice were provided pel-
leted rodent diet (ProLab 3000; Purina 
Mills, Gray Summit, MO) and filtered water 
ad libitum and were maintained in facilities 
accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care 
International. A total of 20 mice (10 mice/
group, body weight = 20 ± 3 g) were housed 
in static microisolator cages (5 mice/cage) on 
heat-treated hardwood bedding, under environ-
mental conditions of 22°C, 40–70% humidity, 
and a 12:12 hr light:dark cycle. All experiments 
were approved by the Massachusetts Institute of 
Technology Committee on Animal Care. The 
animals were treated humanely and with regard 
for the alleviation of suffering. Inorganic arsenic 
(arsenic, 10 ppm) was administered to mice 
(~ 8 weeks of age) as sodium arsenite (Fisher 
Scientific, Waltham, MA) in drinking water for 
4 weeks. Freshly prepared arsenic- containing 
water (10 ppm) was provided to mice every 
Monday and Thursday. Control mice received 
water alone. 
Animal monitoring and histological 
 analy sis. Throughout the experiments, mice 
were assessed daily for evidence of diarrhea, 
dehydration, and deteriorating body condition. 
Mice were euthanized with carbon dioxide and 
necropsied after 4 weeks of arsenic consump-
tion. Formalin-fixed tissues were routinely 
processed, embedded in paraffin, sectioned 
at 4 μm, stained with hematoxylin and eosin, 
and evaluated by a board-certified veterinary 
pathologist blinded to the sample identity. 
Inflammation, edema, epithelial defects, hyper-
plasia, and dysplasia of multi ple regions of liver 
(left lateral, medial, right lateral, and caudate 
lobes) and colon (distal, transverse, and proxi-
mal colon) were scored on an ascending scale 
(0–4, with 0 being normal) of severity and 
invasiveness of the lesion, if any. Pathological 
scores did not show any significant differ-
ence between the control and arsenic-treated 
mice and are not presented here. We also did 
not observe any significant changes in body 
weights, mortality, and food intake.
16S rRNA gene sequencing. We iso-
lated DNA from fecal pellets collected during 
necropsy using a PowerSoil® DNA Isolation 
Kit (MO BIO Laboratories, Carlsbad, 
CA) according to the manufacturer’s 
instructions. The resultant DNA was quanti-
fied by ultraviolet spectroscopy and stored 
at –80°C for further analysis. DNA was 
amplified using universal primers of U515 
(GTGCCAGCMGCCGCGGTAA) and 
E786 (GGACTACHVGGGTWTCTAAT) 
to target the V4 regions of 16S rRNA of bac-
teria. Individual samples were barcoded, pooled 
to construct the sequencing library, then 
sequenced using an Illumina Miseq (Illumina, 
San Diego, CA) to generate pair-ended 
150 × 150 reads.
Analysis of 16S rRNA sequencing data. The 
raw mate-paired fastq files were quality-filtered, 
demultiplexed, and analyzed using Quantitative 
Insights into Microbial Ecology (QIIME) soft-
ware (http://qiime.org). For quality filtering, 
the default parameters of QIIME were main-
tained in which reads with a minimum Phred 
quality score of < 20, containing ambiguous 
base calls and < 113 bp of consecutive high-
quality base calls, were discarded. In addition, 
reads with three consecutive low-quality bases 
were truncated. The samples sequenced were 
demultiplexed using 8-bp barcodes, allowing 
1.5 errors in the barcode. UCLUST software 
(http://www.drive5.com/uclust) was used to 
choose the operational taxonomic units (OTUs) 
with a threshold of 97% sequence simi larity. 
A representative set of sequences from each 
OTU was selected for taxonomic identifi cation 
of each OTU using the Ribosomal Database 
Project (RDP) classifier (http://rdp.cme.msu.
edu). The Greengenes OTUs (4feb2011 build) 
reference sequences (97% sequence similarity) 
were used as the training sequences for RDP 
classifier. A 0.80 confidence threshold was used 
for taxonomic assignment. The taxonomic 
assignment of 16S rRNA sequencing data 
could be achieved at different levels, including 
phylum, class, order, family and genus. Our 
analyses were typically conducted at the fam-
ily level because of the higher confidence in 
the assignment of taxa based on the sequenc-
ing reads; therefore, a significant change at the 
family level may reflect changes of multiple 
gut bacteria at genus and species levels. The 
sequencing data have been deposited in the 
MG-RAST (metagenomics Rapid Annotation 
using Subsystem Technology) server (http://
metagenomics.anl.gov/).
Sample processing for metabolomics. One 
day before euthanasia of the mice, we collected 
urine samples using a metabolic cage with dry 
ice placed around the urine collection vessel to 
prevent oxidation or degradation of metabo-
lites during the collection period (approxi-
mately 16 hr). Fecal pellets were also collected 
from individual animals. We collected plasma 
samples during necropsy. Metabolites were iso-
lated from urine using methanol as described 
previously (Lu et al. 2012). Cold methanol 
(80 μL) was added to 20 μL urine or plasma. 
After vortexing for 1 min, the samples were 
incubated at 4°C for 20 min and then centri-
fuged for 10 min at 12,000 rpm. The super-
natant was collected, dried in a SpeedVac 
(Savant SC110A; Thermo Electron, Waltham, 
MA), and then resuspended in 30 μL 98:2 
water:acetonitrile for MS analysis. Metabolite 
extraction from fecal pellets was conducted in 
a similar manner. Fecal pellets (25 mg) were 
dissolved in 400 μL cold methanol solution 
(50:50 methanol:water), followed by vortex-
ing at maximum speed for 10 min using a 
flat-bed vortex (MO BIO Laboratories). The 
supernatant was centrifuged for 10 min at 
12,000 rpm, dried in a SpeedVac, and then 
resuspended in 30 μL 98:2 water:acetonitrile 
for metabolomics profiling.
Metabolomics profiling. We performed 
LC-MS analyses on a quadrupole- time-of-
flight (Q-TOF) 6510 mass spectrometer 
(Agilent Technologies, Santa Clara, CA) with 
an electro spray ionization source. The mass 
spectrometer was interfaced with an Agilent 
1200 HPLC system. The Q-TOF was cali-
brated daily using the standard tuning solu-
tion from Agilent Technologies. The typical 
mass accuracy of the Q-TOF was < 10 ppm. 
Metabolites were analyzed in the positive 
mode only over a range of 80–1000 m/z using 
a C18 T3 reverse-phase column from Waters 
Corporation (Milford, MA) because of the 
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higher numbers of detected molecular features 
(i.e., metabolites), as demonstrated previously 
(Lu et al. 2012). Metabolomics profiling data 
were processed as described previously (Lu 
et al. 2012). MS/MS was generated on the 
Q-TOF to confirm the identity of perturbed 
metabolites. The metabolomics data were sub-
mitted to the XCMS Online server (https://
xcmsonline.scripps.edu/).
Data processing of metabolomics data. Data 
acquired in Agilent .d format were converted 
to mzXML using MassHunter Workstation 
software from Agilent Technologies. Data 
were filtered by intensity, and only signals 
with intensities > 1,000 were considered. The 
converted data were processed using XCMS 
Online for peak picking, alignment, integra-
tion, and extraction of the peak intensities. 
To profile individual metabolite differences 
between control and arsenic-treatment groups, 
a two-tailed Welch’s t-test was used (p < 0.05). 
The exact masses of molecular features with 
significant changes were searched against the 
Human Metabolome Database (HMDB; 
http://www.hmdb.ca/), METLIN (http://
metlin.scripps.edu), and Kyoto Encyclopedia 
of Genes and Genomes (KEGG) databases 
(http://www.genome.jp/kegg/pathway.html) 
with a 10-ppm mass accuracy threshold. The 
matched exact masses were stored and used for 
the generation of MS/MS data to identify the 
metabolites.
Statistical analysis of data. Principal com-
ponent analysis (PCA) was performed to exam-
ine intrinsic clusters of metabolomics data. A 
95% confidence interval (CI) was used as the 
threshold to identify potential outliers in all 
samples. In addition, heat maps were gener-
ated using a hierarchical clustering algorithm 
to visualize the metabolite difference within the 
data set. Principal coordinate analysis (PCoA) 
was used to compare the gut microbiome pro-
files between the control and treatment. The 
difference in the gut micro biome composi-
tion was further assessed using a non parametric 
test via Metastats software (http://metastats.
cbcb.umd.edu/) as described previously (White 
et al. 2009). The correlation matrix between 
the gut microflora–related metabolites and gut 
bacterial species was generated using Pearson’s 
corelation coefficient.
Results
Workflow to probe functional changes of the 
gut microbiome. The experimental workflow 
combined 16S rRNA gene sequencing and 
metabolite profiling to examine the impact of 
arsenic exposure on the gut microbiome and its 
metabolic profiles (see Supplemental Material, 
Figure S1). Briefly, DNA was isolated from 
fecal pellets, amplified by polymerase chain 
reaction using 16S rRNA–specific primers, fol-
lowed by 150 × 150 bp paired-end sequenc-
ing using the Illumina Miseq platform. The 
resultant sequencing reads were processed using 
the QIIME and Metastats software packages 
to reveal exposure-induced gut microbiome 
changes. For metabolomics analysis, metabo-
lites from fecal pellets, urine, and plasma were 
extracted and analyzed by Q-TOF. Molecular 
features (i.e., all signals associated with a given 
analyte) were further processed and statisti-
cally analyzed with XCMS software to profile 
metabo lites with significant changes (1.5-fold 
change, p < 0.05) between the control and 
arsenic-treated animals. The resultant peak 
list with exact masses was searched against 
metabolite databases, including HMDB and 
METLIN. Next, the matched exact masses and 
associated retention times were used to gener-
ate MS/MS spectra to confirm the metabolite 
identities, followed by metabolic pathway or 
function analysis with the KEGG and HMDB 
databases. Finally, correlations between the 
gut microbiome changes and shifted metabo-
lome were examined to establish the func-
tional impacts of arsenic exposure on the 
gut microbiome.
Arsenic-induced gut microbiome changes. 
Figure 1A shows the identified gut bacteria 
assigned at the family level from 16S rRNA 
sequencing reads, with each color represent-
ing an individual bacterial family (see also 
Supplemental Material, Figure S2A and 
Table S1). In terms of the assignment at 
the phylum level, Firmicutes (52.79%) and 
Bacteroidetes (41.57%) were predomi-
nant in the gut bacteria of mice, followed by 
Tenericutes (3%), Actinobacteria (0.18%), 
Cyanobacteria (0.023%), and Proteobacteria 
(0.0042%), with 2.41% sequences unmatched 
with the database (see Supplemental Material, 
Figure S2B). Our observations and assignments 
of gut bacteria at phylum level are consistent 
with previous reports that the gut microbi-
ome consists of only several phyla (Turnbaugh 
et al. 2006). The taxonomic assignments and 
fold changes of gut bacterial components 
that were significantly changed (p < 0.05) are 
listed in Figure 1B. The difference in the gut 
microbiome patterns arising from arsenic is 
readily differentiated using multivariate statis-
tical analysis, as shown by the PCoA plot in 
Figure 1C. The control and treated animals 
are well separated, with 19.95% and 10.66% 
variation explained by principal component 
(PC) 1 and PC2, respectively. Consistent with 
the PCoA plot, the jackknifed beta diversity 
and hierarchical cluster ing analysis via the 
unweighted pair group method with arithmetic 
mean (UPGMA) demonstrated that all con-
trol and treated animals clustered in their own 
groups, as shown in Figure 1D. In addition, 
control mice clustered into two subgroups in 
the PCoA plot (Figure 1C) and UPGMA hier-
archical clustering analysis (Figure 1D), which 
was attributed to individual variations of gut 
microbiome profiles, as illustrated in Figure 1A.
Arsenic-induced changes in metabolic pro-
files of the gut microbiome. The combination 
in feces of a large quantity of gut bacteria and 
their metabolic products creates an ideal bio-
logical sample to assess functional changes of 
the gut microbiome. Figure 2A illustrates that 
arsenic exposure perturbed the metabolic pro-
files of the gut microbiome, with 146 increased 
and 224 decreased molecular features, respec-
tively. As shown in Figure 2B, the control and 
arsenic-treated groups could be differentiated 
readily using metabolite fingerprints, with an 
excellent separation of the control and arsenic-
treated animals using the first two components 
of PCA (i.e., PC1 and PC2). The hierarchical 
clustering heat map in Figure 2C also shows 
similar clustering patterns of detected molecu-
lar features within each group. Clear separa-
tions of metabolite profiles between control 
and arsenic-treated mice were also observed 
for the urine and plasma samples, with a large 
number of perturbed molecular features (see 
Supplemental Material, Figure S3). A num-
ber of metabolites with > 1.5-fold changes 
between the control and arsenic-treated mice 
were identified (see Supplemental Material, 
Tables S2–S4) using the MS/MS approach (see 
Supplemental Material, Figure S4). The struc-
tures of these metabolites were diverse, includ-
ing amino acid derivatives, bile acids, lipids, 
fatty acids, isoflavones, indole derivatives, and 
glucuronide and carnitine conjugates, with 
many of the metabolites being either directly 
generated or modulated by the gut bacteria.
Correlation between the gut micro-
biome and metabolites. To explore the 
functional correlation between the gut 
microbiome changes and metabolite pertur-
bations, a correlation matrix was generated 
by calculating the Pearson’s correlation coef-
ficient (Figure 3A). Clear correlations could 
be identified between the perturbed gut 
microbiome and altered metabolite profiles 
(p > 0.5 or < –0.5, p < 0.05). Figure 3B lists 
several typical gut microflora–related metabo-
lites that are highly correlated with specific 
gut bacteria to demonstrate the functional 
correlation between the gut microbiome and 
metabolites. For example, indolelactic acid, 
which decreased 11.6-fold in arsenic-treated 
mice, positively correlates with the B9 fam-
ily (p_Tenericutes;f_Erysipelotrichaceae), but 
negatively correlates with the B8 family 
(p_Firmicutes;f_Clostridiales Family XIII 
Incertae Sedis). Likewise, daidzein positively 
correlates with the B4 (p_Firmicutes;f_Other) 
and B7 (p_Firmicutes;f_Clostridiaceae) fami-
lies, respectively. Phenylpyruvic acid, indole-
3- carbinol, and glycocholic acid positively 
correlate with the B2 (p_Cyanobacteria;f_
unassigned), B5 (p_Firmicutes;f_unassigned), 
and B7 (p_Firmicutes;f_Clostridiaceae) 
families, respectively, whereas dihydro daidzein 
negatively correlates with the B8 family 
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(p_Firmicutes;f_Clostridiales Family XIII 
Incertae Sedis). In summary, arsenic exposure 
induces a significant taxonomic perturbation 
in the gut microbiome, which in turn sub-
stantially alters the metabolomic profile of the 
gut micro biome, as evidenced by changes of 
diverse gut microflora–related metabolites.
Discussion
We used high-throughput 16S rRNA gene 
sequencing and metabolomics profiling to 
study the impact of arsenic exposure on the 
gut microbiome and its metabolic profiles. The 
data clearly show that arsenic exposure induced 
a significant change in the gut microbiome 
composition of mice. In addition, these per-
turbed gut bacteria were strongly associated 
with changes of a number of gut microflora–
related metabolites, indicating that arsenic 
exposure not only disturbs gut bacteria at the 
abundance level but also substantially alters the 
metabolomic profile of the gut microbiome, 
resulting in the disturbance of host metabolite 
homeostasis after arsenic exposure. These find-
ings may provide mechanistic insights regard-
ing perturbations of the gut microbiome as a 
new mechanism of environmental chemical–
induced human disease.
Accumulating evidence suggests that meta-
bolic changes associated with gut microbiome 
perturbations are important risk factors for 
inducing abnormal tissue functions resulting 
in diseases such as obesity, insulin resistance, 
and cardiovascular disease (Jones et al. 2008; 
Turnbaugh et al. 2006; Wang et al. 2011). 
The gut microbiome could directly change its 
metabolic capacity and affect intestinal func-
tion locally through microbial products. For 
example, the gut microbiota has a strong effect 
on energy homeostasis in the colon, attributed 
to the use of butyrate produced by gut bacteria 
as the primary energy source for colonocytes 
(Donohoe et al. 2011). Likewise, altered gut 
microbiota can also trigger systemic effects on 
host metabolism in remote tissues such as liver, 
brain, adipose, and muscle because the products 
of microbial metabolism could serve as signal-
ing molecules or act in conjunction with the 
host on the metabolism of diverse chemicals 
to affect individual susceptibility to different 
diseases. For instance, trimethylamine N-oxide, 
a gut microflora–generated metabolite, has 
been identified to be strongly associated with 
athero sclerosis in a large clinical cohort (Wang 
et al. 2011). Dietary choline–enhanced athero-
sclerosis could be inhibited by suppressing 
intestinal microflora in athero sclerosis-prone 
mice, further highlighting the role of perturba-
tions of gut microflora–generated metabolites 
in disease development.
The gut micro biome plays a key role in the 
energy metabolism of the host. Non digestible 
carbohydrates are degraded via fermentation 
in the colon by the gut microbiota to yield 
Figure 1. (A) The gut microbiome composition profiles at the family level in the control and arsenic-
treated mice revealed by 16S rRNA sequencing (each color represents one bacterial family). (B) The 
fold changes and taxa assignments of significantly perturbed gut bacteria in arsenic-treated mice 
compared with controls [Abbreviations: c, class; f, family; o, order; p, phylum; and family abbrevia-
tions: B1  (Other;Other;Other;Other); B2 (p_Cyanobacteria;c_Chloroplast;o_Streptophyta;f_unas-
signed); B3  (p_Firmicutes;c_Bacilli;o_Bacillales;Other); B4  (p_Firmicutes;c_Clostridia;Other;Other); 
B5  (p_Firmicutes;c_Clostridia;o_Clostridiales;f_unassigned); B6  (p_Firmicutes;c_Clostridia;o_
Clostridiales;f_Catabacteriaceae); B7  (p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae); 
B8  (p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiales Family XIII Incertae Sedis); B9  (p_
Tenericutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae).] (C) The gut microbiome pat-
terns of control and arsenic-treated mice differentiated by principal coordinate analysis. (D) Hierarchical 
clustering analysis by UPGMA indicates that controls and arsenic-treated mice clustered in their own 
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energy for the host and metabolic end prod-
ucts such as short-chain fatty acids. Previous 
studies have documented that the imbal-
anced gut microbiome may be associated with 
human diseases such as obesity and diabetes 
(Qin et al. 2012; Turnbaugh et al. 2006). For 
example, Turnbaugh et al. (2006) found that 
obesity was associated with a large shift in the 
relative abundance of the specific taxa pres-
ent, with a statistically significant reduction in 
Bacteroidetes and a significantly greater propor-
tion of Firmicutes in obese mice (Turnbaugh 
et al. 2006). Likewise, transplantation of the 
cecal microbiota from obese mice fed on high-
fat diets into germ-free recipients increases adi-
posity significantly more than transplantation 
of microbiota from lean mice (Turnbaugh 
et al. 2006), further highlighting the role of 
the gut microbiome in affecting the efficiency 
of harvesting energy and defining obese/lean 
phenotypes. Cho et al. (2012) also demon-
strated the influence of gut microbiome per-
turbations on tissue adiposity of the host by 
delineating the effect of antibiotics use in early 
life. These authors discovered substantial taxo-
nomic changes in the gut microbiome, changes 
in primary genes responsible for the metabo-
lism of carbohydrates to short-chain fatty acids, 
and marked alterations in hepatic metabolism 
of lipids and cholesterol. In the present study, 
bacteria in the family of Bacteroidetes were not 
increased by arsenic exposure, whereas four 
Firmicutes families were significantly decreased. 
Arsenic is not an obesogen, but rather has anti-
obesogenic properties, although the mechanism 
remains unknown (Paul et al. 2011). Excess 
accumulation of white adipose tissue in obe-
sity is a risk factor for insulin resistance and 
the development of diabetes because white 
adipose tissue regulates energy balance, lipid, 
and glucose homeostasis, and release a variety 
of signaling factors that affect insulin sensitiv-
ity and inflammation (Rosen and Spiegelman 
2006). However, defects in adipogenesis in adi-
pose tissue can also lead to the development 
of insulin resistance and diabetes (Hou et al. 
2012; Vigouroux et al. 2011). We identified 
several decreased Firmicutes families following 
Figure 2. (A) Arsenic exposure perturbed the metabolic profile of fecal samples of mice, with 370 molecular features being significantly changed compared with 
controls (fold change > 1.5 and p < 0.05). (B) Controls were separated from arsenic-treated mice in metabolite profiles by PCA. (C) Hierarchical clustering heat 
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Figure 3. (A) Correlation plot showing the functional correlation between perturbed gut bacteria families and altered fecal metabolites. (B) Scatter plots illustrating 
statistical association between the relative abundance of altered gut bacteria families and the mass spectrum intensities of some typical gut microflora–related 
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arsenic exposure, and a number of Firmicutes 
species, such as Eubacterium, Faecalibacterium, 
and Roseburia, are known to be butyrate pro-
ducers (Tremaroli and Backhed 2012). Thus, 
an arsenic-altered gut microbiome may affect 
energy harvesting, short-chain fatty acid pro-
duction, and adipo genesis. Another example 
to support arsenic exposure impairment of 
energy metabolism stems from the observa-
tion that fatty acid carnitines were significantly 
reduced in the urine of arsenic-treated mice (see 
Supplemental Material, Table S3). Fatty acid 
carnitines are used to transport fatty acids into 
mitochondria for fatty acid oxidation to gener-
ate metabolic energy; this process may be used 
to compensate for insufficient energy harvest 
due to disturbed gut microbiota after arsenic 
exposure. In agreement with this potential 
mechanism, germ-free mice and lean individu-
als also exhibit increased fatty acid oxidation 
and decreased lipogenesis (Backhed et al. 2007).
Indole-containing metabolites were signifi-
cantly altered in fecal and urine samples after 
arsenic exposure in mice (see Supplemental 
Material, Figure S5A). The presence of the 
altered indole-containing metabolites is highly 
correlated with perturbed gut bacterial families. 
For example, 3-indolepropionic acid may 
serve as a specific indicator of imbalanced gut 
bacteria because a gut bacterial metabolic pro-
cess is needed to synthesize this compound. 
A recent study identified Clostridium sporo-
genes as the only species, among 24 intestinal 
microflora tested, to produce 3-indolepropi-
onic acid (Wikoff et al. 2009). Thus, increased 
excretion of 3-indolepropionic acid in urine 
(+1.8-fold) may indicate that the abundance 
of Clostridium sporogenes or species with simi-
lar functions have increased. In fact, among 
six significantly perturbed Firmicutes families, 
one Firmicutes family significantly increased 
in abundance after arsenic exposure—
p_Firmicutes;c_Clostridia;o_Clostridiales;f_
Clostridiales Family XIII Incertae Sedis, B8 
in Figure 1B, with a +2.0-fold change. In par-
ticular, Clostridium sporogenes and this increased 
gut bacteria family are classified into the same 
order of Clostridiales. The formation of indole-
containing metabolites likely occurs via the 
genera tion of indole by the intestinal bacte-
ria that produce the enzymes to catalyze the 
conversion of tryptophan to indole, followed 
by further enzymatic processing. For example, 
absorbed indole could be converted to indoxyl 
in the liver, and then sulfated to allow for uri-
nary excretion. An increased amount of indoxyl 
in urine (+2.9-fold in arsenic-treated mice) sug-
gests an increased indole production by gut 
bacteria, which also supports the production of 
increased amounts of other urine indole-related 
metabolites such as IPA, indole-3-carboxylic 
acid, and indoleacrylic acid. However, increased 
urinary excretion of indoxyl may also suggest 
that phase I/II biotransformations—including 
hydroxyla tion, sulfation, and glucuronida-
tion—were changed during exposure. In an ele-
gant study, Wikoff et al. (2009) demonstrated 
a broad phase II metabolic response of the host 
to metabolites generated by the microbiome, as 
evidenced by the exclusive presence of numer-
ous sulfated, glycine-conjugated, and glucuro-
nide adducts in the serum of mice with normal 
gut microbiota compared with germ-free mice. 
In the present study, we also found several gluc-
uronide metabolites to be significantly reduced 
in urine (see Supplemental Material, Table S3), 
possibly reflecting an impaired glucuroni dation 
capacity affected by a perturbed gut micro-
biome as a result of arsenic exposure.
Isoflavone metabolites are also sensitive to 
gut microbiome changes (see Supplemental 
Material, Figure S5B). Previously, we discov-
ered that daidzein was significantly increased 
in the serum of Rag2–/– mice infected with 
Helicobacter hepaticus (Lu et al. 2012). The 
increased amount of daidzein was attrib-
uted to an altered gut microflora induced 
by Helicobacter hepaticus infection consis-
tent with previous studies that demonstrated 
that Helicobacter spp. infections perturb 
the gut microflora in mice (Whary et al. 
2006). Daidzein is converted by anaero-
bic bacteria in the large intestine to several 
metabolites—including dihydrodaidzein, 
O-desmethylangolensin, and equol—depend-
ing on the gut bacterial composition of the 
host. In the present study, we detected sig-
nificantly decreased daidzein and dihydro-
daidzein but increased O-desmethylangolensin 
in feces, suggesting that the formation 
of O-desmethylangolensin is favored in 
arsenic-treated mice. Of particular interest, 
O-desmethylangolensin is positively corre-
lated with a Firmicutes family (p_Firmicutes; 
c_Bacilli;o_Bacillales;Other, +9.2-fold in 
arsenic-treated mice). Hur et al. (2000) sug-
gested that several candidate bacteria are par-
ticipating in daidzein metabolism, although 
the intestinal bacteria responsible for daid-
zein metabolism in humans have not been 
unambiguously identified. Nevertheless, 
altered isoflavone metabolites may be used 
as bio indicators to probe changes in the gut 
microbiome composition arising from diverse 
environmental factors such as bacterial 
infections (Lu et al. 2012) and toxic chemicals.
Bile acids and intermediates were signifi-
cantly perturbed in arsenic-treated mice (see 
Supplemental Material, Table S2). Bile acids 
are cholesterol derivatives synthesized in the 
liver, and they undergo extensive entero hepatic 
recycling and gut microbial modification, 
including deconjugation and dehydroxylation. 
Bile acids not only have important functions 
in solubilizing cholesterol and facilitating the 
absorption of cholesterol, fat-soluble vitamins, 
and lipids from the gut, but they also act as 
signaling molecules to regulate metabolic 
homeo stasis by activating diverse nuclear recep-
tors (Nguyen and Bouscarel 2008). In the pres-
ent study, 7-α-hydroxy-3-oxo-4-cholestenoate 
and its degradation product were excreted at 
a higher level in arsenic-treated mice com-
pared with controls. 7-α-hydroxy-3-oxo-4-
cholestenoate is involved in the biosynthesis 
of primary bile acids (Kanehisa et al. 2012), 
and an increased excretion of 7-α-hydroxy-
3-oxo-4-cholestenoate and its degradation 
product may impair the synthesis and entero-
hepatic recycling of bile acids. Likewise, lev-
els of glycocholic acid decreased (–2.3-fold) 
in fecal samples of arsenic-treated mice. These 
altered bile acid species indicate that arsenic 
exposure affects the homeostasis of bile acids. 
The underlying mechanisms remain elusive; 
however, arsenic-induced gut microbiome 
perturbations may play a role in this process. 
Previous studies demon strated a large effect of 
the gut microflora on primary and secondary 
bile acid profiles in tissues of antibiotic-treated 
rats (e.g., Swann et al. 2011). Moreover, speci-
fic microbial bile acid co-metabolites present 
in peripheral tissues and pathway changes 
regulated by farnesoid X receptor indicate a 
broad signaling role for bile acids and high-
light the symbiotic microbial influences in 
bile acid homeostasis in the host (Swann et al. 
2011). Moreover, the role of gut bacteria in 
the regulation of bile acids has raised the ques-
tion of whether bile acids modulated by the 
gut microbiome are associated with regulation 
of the host immune system (Brestoff and Artis 
2013). Previous studies have demonstrated that 
bile acid signaling via their receptors is linked 
to a common anti inflammatory response in 
macro phages and monocytes (Brestoff and Artis 
2013). In particular, it has been reported that 
chronic arsenic exposure signifi cantly com-
promises the immune response to influenza A 
infection (Kozul et al. 2009). Clearly, further 
research is needed to shed light on the role of 
the gut microbiome and its associated metabo-
lites, including bile acids, in arsenic-induced 
impaired immune responses and other diseases.
In the present study, we demonstrated that 
arsenic exposure altered the gut microbiome 
and associated metabolomic profiles. However, 
future studies are warranted to delineate the 
mechanistic basis of these perturbations. As 
shown by the correlation analysis between the 
gut bacteria and metabolites, arsenic exposure 
can induce changes in the gut microbiome 
in terms of abundance, resulting in a shifted 
metabolome in the gut microbiome. Of equal 
importance, arsenic exposure may also cause an 
altered metabolome by affecting the physiology 
of the gut bacteria without changing the spe-
cies and abundance. Therefore, the changes in 
the metabolic profiles of the gut microbiome 
may not entirely depend on shifts in the spec-
trum of microbes revealed by 16S rRNA gene 
sequencing. Such metabolic changes could be 
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achieved via other mechanisms besides alter-
ing the types and numbers of bacteria present 
in the gut, such as the regulation of gene and 
protein expression in a bacterium. Maurice 
et al. (2013) have recently demonstrated that 
xenobiotics significantly altered the physiol-
ogy and gene expression of the human gut 
microbiome. Therefore, metatranscriptomics 
and meta proteomics profiling are warranted in 
the future to elucidate the role of arsenic expo-
sure in altering the functions of the gut micro-
biome, which encodes 100-fold more unique 
genes than the human genome and profoundly 
modulates host metabolism (Ley et al. 2006).
Our findings show that arsenic exposure 
perturbs the gut microbiome composition 
and associated metabolic profiles in mice and 
represents an initial and critical step toward 
understanding how arsenic exposure affects 
the gut microbiome and its functions. Future 
studies are needed to address many intriguing 
questions in this exciting field. For example, it 
remains to be determined whether any changes 
to the gut microbiome and its associated 
metabolites occur in arsenic-exposed humans 
because there are differences in the gut micro-
biome between mice and humans. The use of 
epidemiological studies combined with experi-
ments in humanized gnotobiotic mice will 
allow researchers to better address species dif-
ferences and elucidate the inter action between 
arsenic exposure and the gut microbiome in 
humans. In addition, whereas we treated mice 
with 10 ppm arsenic for 4 weeks, humans are 
usually exposed to much lower doses of arsenic 
for longer periods. Thus, the dose- and time-
dependent effects of arsenic exposure on the 
gut microbiome also need to be defined. Of 
particular importance is how arsenic impacts 
the gut microbiome during the windows of 
susceptibility because the establishment of the 
gut microflora is a temporal process occurring 
after birth (Palmer et al. 2007). Thus, arsenic-
induced perturbations in the gut micro biome 
may have age-related effects. Likewise, answers 
to other issues, such as sex-specific influences, 
persistent effects of arsenic on the microbiome 
after cessation of exposure, and correlations 
between gut microbiome changes and toxicity 
phenotypes, all await future studies.
Conclusions
We combined 16S rRNA sequencing and 
metabolomics to analyze the impact of arsenic 
on the gut microbiome and its metabolic pro-
files in mice. The sequencing revealed that 
arsenic exposure significantly altered the gut 
microflora composition, whereas the metabo-
lomics experiments showed that a number of 
metabolites involved in diverse metabolic path-
ways were substantially perturbed after expo-
sure to arsenic. In addition, correlation analysis 
identified that some gut bacteria families were 
highly correlated with altered gut microflora–
related metabolites. Taken together, these data 
indicate that arsenic exposure not only per-
turbs the gut microbiome at the abundance 
level but that it also alters metabolic profiles of 
the gut microbiome, supporting the hypothe-
sis that perturbations of the gut micro biome 
may serve as a new mechanism by which 
arsenic exposure leads to or exacerbates human 
diseases. Furthermore, these modulated gut 
 microflora– related metabolites may be potential 
biomarkers useful for probing the functional 
impacts of arsenic and other diverse environ-
mental chemicals on the gut microbiome.
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